Webinar Slides

FROM THE BENCH AND IN THE TRENCHES:
JUDGE, PLAINTIFF, AND DEFENDANT
PERSPECTIVES ON PRODUCTS LIABILITY:
MASS TORTS
JUDGE MARINA CORODEMUS (RET.)
WEDNESDAY, SEPTEMBER 24, 2014
2:00 - 3:00 P.M. EDT
Medmarc.com
JUDGE MARINA CORODEMUS (RET.)
[email protected]
Judge Marina Corodemus is the Director
of the ADR Practice of Corodemus &
Corodemus, a dedicated Alternative
Dispute Resolution Firm that serves an
national clientele in the areas of
Mediation, arbitration and Special Master.
732-603-0005. She is the former Mass
Court Judge in New Jersey. Judge
Corodemus now serves as Special Master
in two of the largest MDL Mass tort cases
in Federal Court and the largest
environmental cases in any State Court.
9/24/2014
2
ELLEN RELKIN ESQUIRE-PLAINTIFF
Ellen Relkin is, Of Counsel to the firm Weitz &
Luxemberg, in their New York City office. Ms. Relkin,
whose practice focuses on pharmaceutical and
medical device product liability and toxic tort matters,
has represented plaintiffs injured by the metal on
metal hip implants including the DePuy ASR, the
Stryker Rejuvenate, Biomet Magnum, as well as the
birth control patch Ortho Evra, the oral contraceptive
Yaz, Hydroxycut dietary supplement products, among
other defective medical products. She currently serves
as co-chair of the plaintiffs National steering
Of Counsel
Weitz & Luxenberg, P.C. committee for DePuy Hip law suits and lead counsel
[email protected]
for the New Jersey Stryker Rejuvenate litigation. She
(212) 558-5715
has been the strategist and author of many prominent
mass tort litigation teams. Ms. Relkin is a certified trial
attorney in the State of New Jersey.
9/24/2014
3
PAUL J. (P.J.) COSGROVE
P.J. represents medical device and pharmaceutical
manufacturers in pattern litigation or mass torts
(particularly “multidistrict litigation”), and in “oneoff” product liability suits, serving as national
coordinating and trial counsel in both large,
complex matters, and individual cases.
Partner, [email protected]
513.698.5034
9/24/2014
4
WHAT IS A MASS TORT? WHO CARES?
 A mass tort is a civil action involving numerous plaintiffs against one or a few
corporate defendants in state or federal court. Law firms sometimes use mass
media to reach possible plaintiffs.
 The three main categories of mass torts include:
 Mass disaster torts
 Mass toxic torts
 Product liability torts
 In U.S. federal courts, mass tort claims are often consolidated as multidistrict
litigation. In some cases, mass torts are addressed through class action.
 Wikipedia
9/24/2014
5
HOW DOES A CASE BECOME MASS TORT?
 FEDERAL LEVEL:
 28 USC 1407 The Judicial Panel on Multidistrict Litigation (“the Panel”)
 State Courts:
 New Jersey: Supreme Court formally promulgated Rule 4:38A to provide for the
centralized management of mass torts in New Jersey. This rule provides that:
 The Supreme Court may designate a case or category of cases as a mass tort to receive
centralized management in
 accordance with criteria and procedures promulgated by the administrative Director
of the Courts upon
 approval by the Court. Promulgation of the criteria and procedures will include
posting in the Mass Tort Information Center on the Judiciary’s Internet website
 (www.judiciary.state.nj. us).
9/24/2014
6
ARE ALL MASS TORTS CLAS S ACTIONS?
 Is the reverse true?
9/24/2014
7
PLAINTIFFS’ CONSIDERATIONS IN MT?
Selecting litigations
-reviewing the medical and scientific literature
-assessing warning labels and what was known about the risks
-considering alternative causes for the injuries
Defining the plaintiff and case criteria
-case screening challenges
-magnitude of injury
-impact of internet on clients hiring multiple counsel
Selecting forum/venue(s)
- Should the cases be coordinated?
-Are there multiple feasible venues and if so, utilize multiple fronts
9/24/2014
8
DEFENSE CONSIDERATIONS?
1. 1. Stop a Mass Tort Before It Starts
2. 2. Make Plaintiffs Prove a Prima Facie Case
3. 3. Science Matters
4. 4. Think Outside New Jersey
5. 5. Candor and Collegiality Count
6. 6. Pick Your Battles Wisely
7. 7. Preserve, Preserve, Preserve
8. 8. Think Globally
9. 9. Act Locally: Get and Use Local Counsel
10. 10. Play Nice

Top 10 Tips for Defending Mass Torts in NJ

By James J. Ferrelli and Alyson B. Walker

June 2011 LJN's Product Liability Law & Strategy
9/24/2014
9
THE DEFENSE RESPONSE
 Coordinate Cases in One Federal (MDL) Court With Independent
Judges
 Force State Court Actions Into One or Two “Home” Courts Where
Coordination Also Is Possible
 Insist on Coordinated Discovery and Properly Phased Trials
REMOVAL TO FEDERAL COURT
28 U.S.C. SEC. 1446(B)
 A lawsuit may be removed within 30 days after the “initial pleading’
that establishes complete diversity “except that a case may not be
removed on the basis of [diversity] jurisdiction more than 1 year
after commencement of the action.”
 “Fraudulent Joinder (pharmacies, sales reps, other manufacturers
and distributors) physicians.
CASE MANAGEMENT
IN MASS TORT LITIGATION
IN RE ENGLE CASES, ___ F.3D ___, 2014 WL
4435893, *10 (11TH CIR. SEPT 10, 2014)
 “the Special Master compiled data on the 1,724 questionnaires that counsel submitted on time. A
number of problems cropped up; for example, 521 personal injury plaintiffs had been dead at the
time of filing—some for quite a long time; 66 wrongful death actions were brought on behalf of
“survivors” of a smoker who was still alive; 64 wrongful death cases involved deceased smokers
with no survivors; and 39 wrongful death cases involved smokers who died more than two years
before the Engle class action was filed (as noted, Florida's wrongful death statute has a two-year
limitations period,) [ ]). [ ] These problems and others led the Special Master to conclude that
even “the current universe of 1,700 cases [in which questionnaires were returned] is still inflated
to an unknown extent by (1) less than enthusiastic or capable plaintiffs and (2) weak, even
nonviable, claims.” Id. at 4.

 “For today's purposes, we only focus on two of these problems: the predeceased personal injury
plaintiffs and the decedent-smokers who died more than two years before Engle was filed. It is
worth noting before we proceed that the questionnaire process culled hundreds more cases from the
District Court's docket, including over 1,000 in which no questionnaire was ever submitted, even
after the court twice allowed plaintiffs' counsel to submit late questionnaires.
9/24/2014
13
AUTHORITY FOR LONE PINE ORDERS?
 No federal rule expressly authorizes use of Lone Pine orders
 The “Lone Pine” decision was an unpublished trial court decision
from NJ involving an unusual toxic tort claim and thousands of
plaintiffs
 NJ Appellate courts have declined to follow “Lone Pine” since expert
reports are to follow fact discovery
 Federal judges enter Lone Pine orders based on wide discretion to
manage discovery under Rule 16 and supporting case law
FED. R. CIV. P. 16(C)(2)(L)
 The Court may consider and take appropriate action on the
following matters:
adopting special procedures for managing potentially difficult or protracted actions
that may involve complex issues, multiple parties, difficult legal questions, or unusual
proof problems.
REQUIREMENTS OF LONE PINE ORDERS
 Basic facts usually provided in fact sheet or discovery responses
detailing exposure and alleged injuries
 Documentation supporting such allegations
Physician certification of drug usage and injury
Records documenting exposure
 Expert reports describing theories of general/specific causation
 Statements regarding specific issues or defenses, such as statute of
limitations
TIMING
 Before discovery?
 Strudley (Colo.2d Jud. Dist. Ct.)
 Acuna (5th Circuit)
 Or after (some) discovery?

Vioxx (E.D. Louisiana)

Fosamox (S.D. New York)
 In relation to settlement?
COUNTERARGUMENTS
 Cuts off plaintiff’s right to discovery and is contrary to the rules of







civil procedure
Only appropriate in rare situations
Misunderstood and improperly used term and tool
Interferes with protections of rules governing summary judgment
Overly burdensome
Shifts burden
May be appropriate only for cases that reject settlement
Not needed as ordinary discovery tools can obtain the needed
information
BELLWETHER TRIALS GOOD OR BAD?

Developments in Selection and Trial of Bellwether Cases Paul D. Rheingold Rheingold, Valet, Rheingold, McCartney
& Giuffra LLP New York, New York
 A common solution for the problem of trying a mass of
cases arising out of the same disaster is first to try a
selected group of plaintiffs. This approach has been
called many things, including a test case, representative
plaintiff trial, and a bellwether case. Plaintiffs selected
will have cases that will aid in deciding issues for the
long run in the litigation. The early outcome may, at a
minimum, help the judge and the parties learn more
about the realities of liability and damages for all cases.
The outcome can also be planned to have a binding effect
upon cases yet to be tried through the operation of
collateral estoppel or using verdicts for plaintiffs for
aggregation.
9/24/2014
19
BELLWETHER WHAT?
 The "bellwether" concept (so named for the lead sheep in a flock which wore the
bell) suggests a lead case, one plaintiff as a stand-in for all. The "representative"
term more often refers to a group of plaintiffs whose claims are typical of the
variety of plaintiffs in the group, e.g., those who may differ because of the type of
injuries, or their mode of exposure, or some legal defenses. The "test case" falls
somewhere in between. § 10:46 Law and powers in use of test cases Research
References West's Key Number Digest, Federal Civil Procedure rs=1951 It is
generally believed that the courts have the rights arising out of inherent powers
of case management to select representative cases to be tried in lieu of trying all
plaintiffs‘ cases at one time. This would be so under a class action, a
consolidation or other means of congregations of cases. In an asbestos case, the
Fifth Circuit found, however, that a court would be overstepping its power in the
use of representative plaintiffs if the outcome of that litigation were used to
decide the liability for an entire class of asbestos
 10-
9/24/2014
20
CHOICE OF LAW? MINE IS BETTER THAN
YOURS
 How does a court decide which law to apply?
 How is that done?
 Why is it Important?
9/24/2014
21
EXPERT TESTIMONY
 DAUBERT
 FRYE
 DAUBERT LITE
9/24/2014
22
E-DISCOVERY IN MASS TORTS

Takeda Part One: Prelude To Disaster? — Takeda Can’t Narrow Its Broadly-Written Litigation Hold

By Michael C. Landis on April 14, 2014

Posted in Legal Decisions & Court Rules
 An opinion from Judge Rebecca Doherty in In re Actos (Pioglitazone)
Products Liability Litigation, MDL No. 11-2299, provides valuable
lessons on the consequences of drafting overly-broad litigation hold
notices, as well as the importance of providing evidence from
knowledgeable witnesses in defense of document retention procedures.
 In a Rule 37 and spoliation motion, the plaintiffs alleged that defendants,
Takeda Pharmaceuticals U.S.A., Inc. and several of its affiliates in the
United States, Japan, and Europe (collectively “Takeda”), purposefully
deleted the files of 46 former employees, including several high-level
officers. The plaintiffs sought a default judgment or, in the alternative, a
combination of sanctions that included an adverse inference jury
instruction, cost-shifting, and a fine.
9/24/2014
23
SANCTIONS FOR WHAT COURT CONSIDERED
SPOLIATION OF ESI
 In re Actos (Pioglitazone) Products Liability Litigation, 2014 WL
355995 (W.D. La. Jan. 30, 2014) (“Actos”)
9/24/2014
24
SPECIAL MASTER LIEN RESOLUTION CLAIMS
 Role of:
 SPECIAL MASTER
 LIEN RESOLUTION
CLAIMS MANAGER
9/24/2014
25
KANSAS SUPREME COURT ADOPTING THE DEFINITION OF
“AGGREGATE SETTLEMENT” FOUND IN THE ALI PRINCIPLES
 A non-class action aggregate settlement is a settlement
of the claims of two or more individual claimants in
which the resolution of the claims is interdependent. Key
features of interdependency are a condition that a
specific percentage of claimants must accept the
settlement and an allocation among the claimants of a
maximum aggregate settlement fund under which each
claimant cannot accept or reject his or her share of the
settlement without affecting the other claimants'
settlement shares. TILZER, v. DAVIS, 288 Kan. 477, 204 P. 3rd
617. (Kansas Supreme Court 2009>)
9/24/2014
26
ETHICS IN MASS TORTS
 CLIENT PLAINTIFF
 CLIENT DEFENDANT
 PLAINTIFF ATTORNEY
 DEFENSE ATTORNEY
9/24/2014
27
MASS TORTS GO GLOBAL
9/24/2014
28
QUESTIONS?
9/24/2014
29